<DOC>
	<DOCNO>NCT02825836</DOCNO>
	<brief_summary>M7583 investigational drug evaluate treatment patient B-cell malignancy , cancer form B cell ( cell part immune system ) . This study design ass use study drug patient B-cell lymphoma try respond well ( B-cell lymphoma come back ) least one three type treatment cancer . This Phase I/II study , mean look several dose level investigational medication term safety well tolerated multiple dos . The final select dose test activity tumor specific population lymphoma ( Mantle cell lymphoma Diffuse Large B Cell Lymphoma )</brief_summary>
	<brief_title>BTK Inhibitor B Cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Patient population In dose escalation cohort : Patients pathologically confirm B cell malignancy ( i.e . DLBCL , CLL , small lymphocytic lymphoma [ SLL ] , follicular lymphoma [ FL ] , mantle cell lymphoma ( MCL ) , Morbus Waldenström ) , least 1 , 3 prior line therapy . In dose expansion cohort : Patients relapsed/refractory DLBCL ( ABC subtype ) histopathologically confirm gene expression profile ( GEP ) test central laboratory MCL document overexpression either cyclin D1 ( 11 ; 14 ) , least 1 , 3 prior line therapy , measurable disease accord Cheson criterion . Life expectancy great 4 month first dose M7583 Eastern Cooperative Oncology Group ( ECOG ) performance status less equal ( &lt; = ) 2 Screening Adequate hematological function absence transfusion define ( within 6 week prior first dose study medication ) define white blood cell ( WBC ) count great equal ( &gt; = ) 3 x 109/liter ( L ) absolute neutrophil count ( ANC ) &gt; = 1.0 x 109/L , platelet count &gt; = 50 x 109/L , haemoglobin &gt; =9 gram per decilitre ( g/dL ) . Adequate hepatic function define total bilirubin level &lt; = 1.5 x upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) &lt; = 2.5 x ULN , alanine aminotransferase ( ALT ) &lt; = 2.5 x ULN . Adequate renal function define estimate glomerular filtration rate ( GFR ) great ( &gt; ) 45 milliliter per minute ( mL/min ) accord 4component Modification Diet Renal Disease ( MDRD ) equation . ( GFR [ mL/min/1.73 m2 ] = 175 x serum creatinine ( Scr ) 1.154 x age0.203 x 1.212 [ African American ] x 0.742 [ female ] ) . Documented disease progression ( base Cheson Halleck criterion ) recent treatment regimen . The patient must also agree pretreatment ontreatment tumor biopsy affect lymph node bone marrow aspirate bone marrow involve . Adult male female patient age ≥ 18 year . Previous exposure BTK inhibitor . Known central nervous system lymphoma leukemia . History Richter 's transformation prolymphocytic leukemia . Prior therapy : Anticancer treatment chemotherapy , immunotherapy , hormonal therapy , biologic therapy , anticancer therapy within 28 day prior Cycle 1 Day 1 ( C1D1 ) trial drug treatment ; ( 6 week nitrosurea mitomycin C ) . Any investigational agent within 28 day prior C1D1 trial drug treatment . Not recovered toxicity due prior therapy , pretherapy status Grade 1 less ( except alopecia ) . Received surgical intervention within 21 day prior C1D1 M7583 treatment receive prior allogeneic stem cell transplant autologous bone marrow transplantation within 6 month prior first dose M7583 . Current significant cardiac conduction abnormality , include correct QT duration ( QTc ) prolongation &gt; 480 msec history past paroxysmal atrial fibrillation significant cardiac arrhythmia . A history cardiovascular/cerebrovascular disease follow : fully recover cerebral vascular accident/stroke ( &lt; 6 month prior enrolment ) , myocardial infarction ( less ( &lt; ) 6 month prior enrolment ) , unstable angina congestive heart failure ( New York Heart Association Classification Class &gt; = II ) . Current hypertension uncontrolled medication . Concomitant treatment nonpermitted drug , include limited , warfarin Vitamin K antagonist . Patients receive medication , herbal supplement , food know moderate strong inhibitor CYP3A within 7 day prior first dose M7583 , moderate strong inducer CYP3A within 21 day prior first dose M7583 , drug mainly metabolize CYP3A narrow therapeutic index stop first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>M7583</keyword>
	<keyword>Bruton 's Tyrosine Kinase Inhibitor</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Open</keyword>
	<keyword>Phase I</keyword>
</DOC>